Independent and joint association of sarcopenia and frailty with mortality in older patients with gastrointestinal cancer: a cohort study with prospective data collection
- PMID: 38015271
- DOI: 10.1007/s00520-023-08173-9
Independent and joint association of sarcopenia and frailty with mortality in older patients with gastrointestinal cancer: a cohort study with prospective data collection
Abstract
Purpose: Sarcopenia and frailty are associated with mortality in older patients with gastrointestinal cancer. However, it is unclear if there is an additional risk when both are present. This study aimed to investigate the independent and overlapping of sarcopenia and frailty with mortality in this population.
Methods: A prospective cohort study including older patients (≥ 60 years old) with gastrointestinal cancer. Sarcopenia was defined by the EWGSP2 criteria: (i) low muscle strength (handgrip test), (ii) low muscle mass (skeletal muscle index), and/or low muscle quality (skeletal muscle radiodensity) by computed tomography. Frailty was defined according to Fried phenotype (at least three of the five components): (i) low muscle strength (handgrip test), (ii) unintentional weight loss, (iii) self-reported exhaustion, (iv) low physical activity, and (v) low gait speed. Cox proportional hazards model was used to assess overall survival rates and risk of mortality.
Results: We evaluated 179 patients with gastrointestinal cancer [68.0 (61.0-75.0) years old; 45% women]. The prevalence of sarcopenia, frailty, and sarcopenia-frailty was 32.9% (n = 59), 59.2% (n = 106), and 24.6% (n = 44), respectively. The incidence of mortality was 27.9% (n = 50) over a 23-month (IQR, 10, 28) period. There was an association of sarcopenia (HR = 1.78, 95% CI 1.03-3.06) with mortality, but no association was found of frailty and the outcome. Sarcopenia-frailty was associated with the highest risk of mortality (HR = 2.23, 95% CI 1.27-3.92).
Conclusion: Sarcopenic-frail older patients with gastrointestinal cancer have a higher risk of mortality than those with sarcopenia or frailty alone, which reinforces the importance of assessing both conditions in oncology clinical care.
Keywords: Adverse outcome; Gait speed; Handgrip strength; Muscle mass; Oncology; Weight loss.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Comment in
-
Correspondence: Methodological considerations in evaluating sarcopenia and frailty in elderly gastrointestinal cancer patients.Support Care Cancer. 2024 Jan 25;32(2):130. doi: 10.1007/s00520-024-08336-2. Support Care Cancer. 2024. PMID: 38270696 No abstract available.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Pilleron S, Sarfati D, Janssen-Heijnen M et al (2019) Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer 144:49–58. https://doi.org/10.1002/ijc.31664 - DOI - PubMed
-
- Muscaritoli M, Arends J, Bachmann P et al (2021) ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr 40:2898–2913. https://doi.org/10.1016/j.clnu.2021.02.005 - DOI - PubMed
-
- Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169 - DOI - PubMed
-
- Xia L, Zhao R, Wan Q et al (2020) Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med 9:7964–7978. https://doi.org/10.1002/cam4.3428 - DOI - PubMed - PMC
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources